The Administrative Core provides oversight to the SPORE and provides the framework for a comprehensive coordination of Projects, Cores, Career Development and Developmental Pilot Programs. The work of the Core is coordinated by the SPORE PI and co-PI's working with the Executive Committee (EC). The EC is responsible for evaluating Projects on a regular basis, setting budgets, and when appropriate promoting Developmental Pilot Projects and research done as part of the Career Development Awards as full Projects. The planning and evaluation process of the Core is accomplished through monthly meetings of the EC. In addition, the EC and the Core are responsible for competing the Developmental Pilot Program and the Career Development Awards. The Core also is responsible for coordinating reviews by the Internal and External Advisory Committees, reporting progress to the NCI at regular intervals, and coordinating SPORE related continuing education to both internal and external audiences. The Core also manages any SPORE supplements and coordinates joint activities with other SPOREs, NCI, EDRN, GOG, PLCO, and other collaborative groups. Going fonward the Core will also take responsibility for coordinating the International Ovarian Cancer Community through a biannual ovarian cancer research meetings held in Greece.
The Administrative Core is necessary for evaluating, executing, and coordinating the activities of the Projects, Cores, Developmental Pilot Programs, Career Development Awards, and other inter-SPORE and collaborative efforts.
|Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870|
|Chiang, Cheryl Lai-Lai; Kandalaft, Lana E (2018) In vivo cancer vaccination: Which dendritic cells to target and how? Cancer Treat Rev 71:88-101|
|Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15|
|Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7|
|Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384|
|Beck, Tim N; Smith, Chad H; Flieder, Douglas B et al. (2017) Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. Head Neck 39:E34-E39|
|Yang, Lu; Zhang, Youyou; Shan, Weiwei et al. (2017) Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9:|
|Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637|
|Zhang, Dongmei; Zhang, Gao; Hu, Xiaowen et al. (2017) Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res 77:3745-3757|
|Prudnikova, Tatiana Y; Chernoff, Jonathan (2017) The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases 8:193-198|
Showing the most recent 10 out of 323 publications